scholarly journals Successful treatment of diffuse large B-cell lymphoma with secondary hemophagocytic lymphohistiocytosis by R-CHOP-E regimen: a case report

2019 ◽  
Vol 48 (2) ◽  
pp. 030006051988223
Author(s):  
Ran Wu ◽  
Xiaohui Deng ◽  
Siguo Hao ◽  
Liyuan Ma

Hemophagocytic lymphohistiocytosis (HLH) is a rare fatal clinical syndrome characterized by a hyperinflammatory condition caused by aberrantly activated macrophages and cytotoxic T cells, resulting in a cytokine storm and organ impairment. Lymphoma, especially B-cell lymphoma in Japan, is a common trigger of secondary HLH. In China, however, most cases of HLH secondary to lymphoma occur in patients with T-cell/natural killer-cell lymphoma or Hodgkin`s lymphoma; HLH is relatively uncommon in patients with B-cell non-Hodgkin’s lymphoma. We herein describe a man with diffuse large B-cell lymphoma (DLBCL) and secondary HLH who was successfully treated by R-CHOP-E chemotherapy. All symptoms resolved and laboratory indications of HLH normalized, and complete remission of the lymphoma was achieved. This rare case highlights not only the possibility of HLH secondary to DLBCL but also the importance of early initiation of R-CHOP-E chemotherapy.

2018 ◽  
Vol 2018 ◽  
pp. 1-5 ◽  
Author(s):  
Cyrus Askin ◽  
Ashley Burris ◽  
Clifton Layman ◽  
Brian Haney ◽  
Jordan Hall

Secondary hemophagocytic lymphohistiocytosis (HLH) in adults is a rare, often fatal syndrome characterized by widespread immune dysregulation. It is seen as a complication of infections, autoimmune diseases, and malignancies. Among the malignancy-related causes, aggressive T-cell or NK-cell neoplasms are most notable, while B-cell lymphomas are less commonly implicated. We present the case of a 32-year-old male transferred to our facility with concern for HLH. During the first week of his hospitalization, his diagnosis was confirmed and the patient demonstrated spontaneous improvement in his symptoms prompting us to delay therapy while searching for a primary cause. In the second week, the patient deteriorated, leading us to initiate steroid monotherapy in the absence of a cause for his HLH. Meanwhile, pathology results from an excisional lymph node biopsy confirmed a diagnosis of T-cell/histiocyte-rich large B-cell lymphoma (TCHRLBCL). Subsequently, we initiated therapy with dose-adjusted R-EPOCH. The patient achieved a complete remission of both HLH and TCHRLBCL as well as a complete return to his prior functional status. In our review of the literature, this represents only the second documented case of HLH associated with TCHRLBCL and the only documented case of an adult experiencing significant spontaneous recovery in this context.


2016 ◽  
Vol 146 (suppl_1) ◽  
Author(s):  
Asa Rubin ◽  
Laura Biederman ◽  
Upasana Joneja ◽  
Dimath Alyemni ◽  
Jerald Gong ◽  
...  

2014 ◽  
Vol 56 (5) ◽  
pp. 1521-1523 ◽  
Author(s):  
Vahid Entezari ◽  
Eberechi Agwa ◽  
Sory J. Ruiz ◽  
Steven A. Lietman ◽  
Bernard J. Silver ◽  
...  

2014 ◽  
Vol 75 (7) ◽  
pp. 673-676 ◽  
Author(s):  
Sasijit Vejbaesya ◽  
Pradermchai Sae-Tam ◽  
Archrob Khuhapinant ◽  
Duangporn Srinak

2017 ◽  
Vol 21 (1) ◽  
pp. 95-99
Author(s):  
Jonathan L Metts ◽  
Sunita I Park ◽  
Michael A Briones ◽  
Frank G Keller

Hemophagocytic Lymphohistiocytosis (HLH) is a hyperinflammatory disorder that may be encountered as a primary or secondary phenomenon. HLH secondary to lymphoma has been described, more frequently in adults than in children. T-cell/Histiocyte-rich B-cell lymphoma (THRLBCL) is a large B-cell lymphoma that resides in a microenvironment of robust host immune response and has previously been associated with HLH in adults. Here, we describe the first case of HLH secondary to THRLBCL in an adolescent patient.


2007 ◽  
Vol 137 (4) ◽  
pp. 364-373 ◽  
Author(s):  
Sverker Hasselblom ◽  
Margret Sigurdadottir ◽  
Ulrika Hansson ◽  
Herman Nilsson-Ehle ◽  
Börje Ridell ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document